Idioma:

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, Hui ; Korn, Joshua M ; Ferretti, Stéphane ; Monahan, John E ; Wang, Youzhen ; Singh, Mallika ; Zhang, Chao ; Schnell, Christian ; Yang, Guizhi ; Zhang, Yun ; Balbin, O Alejandro ; Barbe, Stéphanie ; Cai, Hongbo ; Casey, Fergal ; Chatterjee, Susmita ; Chiang, Derek Y ; Chuai, Shannon ; Cogan, Shawn M ; Collins, Scott D ; Dammassa, Ernesta ; Ebel, Nicolas ; Embry, Millicent ; Green, John ; Kauffmann, Audrey ; Kowal, Colleen ; Leary, Rebecca J ; Lehar, Joseph ; Liang, Ying ; Loo, Alice ; Lorenzana, Edward ; Robert McDonald, 3rd, E ; McLaughlin, Margaret E ; Merkin, Jason ; Meyer, Ronald ; Naylor, Tara L ; Patawaran, Montesa ; Reddy, Anupama ; Röelli, Claudia ; Ruddy, David A ; Salangsang, Fernando ; Santacroce, Francesca ; Singh, Angad P ; Tang, Yan ; Tinetto, Walter ; Tobler, Sonja ; Velazquez, Roberto ; Venkatesan, Kavitha ; Von Arx, Fabian ; Wang, Hui Qin ; Wang, Zongyao ; Wiesmann, Marion ; Wyss, Daniel ; Xu, Fiona ; Bitter, Hans ; Atadja, Peter ; Lees, Emma ; Hofmann, Francesco ; Li, En ; Keen, Nicholas ; Cozens, Robert ; Jensen, Michael Rugaard ; Pryer, Nancy K ; Williams, Juliet A ; Sellers, William R

Nature medicine, 2015-11, Vol.21 (11), p.1318-1325 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Autor: Gao, Hui ; Korn, Joshua M ; Ferretti, Stéphane ; Monahan, John E ; Wang, Youzhen ; Singh, Mallika ; Zhang, Chao ; Schnell, Christian ; Yang, Guizhi ; Zhang, Yun ; Balbin, O Alejandro ; Barbe, Stéphanie ; Cai, Hongbo ; Casey, Fergal ; Chatterjee, Susmita ; Chiang, Derek Y ; Chuai, Shannon ; Cogan, Shawn M ; Collins, Scott D ; Dammassa, Ernesta ; Ebel, Nicolas ; Embry, Millicent ; Green, John ; Kauffmann, Audrey ; Kowal, Colleen ; Leary, Rebecca J ; Lehar, Joseph ; Liang, Ying ; Loo, Alice ; Lorenzana, Edward ; Robert McDonald, 3rd, E ; McLaughlin, Margaret E ; Merkin, Jason ; Meyer, Ronald ; Naylor, Tara L ; Patawaran, Montesa ; Reddy, Anupama ; Röelli, Claudia ; Ruddy, David A ; Salangsang, Fernando ; Santacroce, Francesca ; Singh, Angad P ; Tang, Yan ; Tinetto, Walter ; Tobler, Sonja ; Velazquez, Roberto ; Venkatesan, Kavitha ; Von Arx, Fabian ; Wang, Hui Qin ; Wang, Zongyao ; Wiesmann, Marion ; Wyss, Daniel ; Xu, Fiona ; Bitter, Hans ; Atadja, Peter ; Lees, Emma ; Hofmann, Francesco ; Li, En ; Keen, Nicholas ; Cozens, Robert ; Jensen, Michael Rugaard ; Pryer, Nancy K ; Williams, Juliet A ; Sellers, William R
Assuntos: Animals ; Antineoplastic Agents - therapeutic use ; Breast Neoplasms - drug therapy ; Cancer ; Carcinoma - drug therapy ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Pancreatic Ductal - drug therapy ; Care and treatment ; Clinical trials ; Colorectal Neoplasms - drug therapy ; Disease Models, Animal ; Female ; Genotype & phenotype ; High-Throughput Screening Assays - methods ; Homeopathy ; Humans ; Lung Neoplasms - drug therapy ; Materia medica and therapeutics ; Melanoma - drug therapy ; Mice ; Neoplasm Transplantation ; Neoplasms - drug therapy ; Pancreatic Neoplasms - drug therapy ; Pharmacology ; Reproducibility of Results ; RNA sequencing ; Skin Neoplasms - drug therapy ; Stomach Neoplasms - drug therapy ; Therapeutics ; Tumors ; Xenograft Model Antitumor Assays - methods ; Xenotransplantation
É parte de: Nature medicine, 2015-11, Vol.21 (11), p.1318-1325
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Profiling candidate therapeutics with limited cancer models during preclinical development hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous patient responses for patient-selection strategies. We established ∼1,000 patient-derived tumor xenograft models (PDXs) with a diverse set of driver mutations. With these PDXs, we performed in vivo compound screens using a 1 × 1 × 1 experimental design (PDX clinical trial or PCT) to assess the population responses to 62 treatments across six indications. We demonstrate both the reproducibility and the clinical translatability of this approach by identifying associations between a genotype and drug response, and established mechanisms of resistance. In addition, our results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities. We therefore propose that this experimental paradigm could potentially improve preclinical evaluation of treatment modalities and enhance our ability to predict clinical trial responses.
Editor: United States: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

United States: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.